Brokerages Anticipate Aptose Biosciences Inc. (NASDAQ:APTO) to Announce -$0.13 Earnings Per Share

Equities research analysts expect that Aptose Biosciences Inc. (NASDAQ:APTOGet Rating) (TSE:APS) will post earnings of ($0.13) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.14). Aptose Biosciences posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 13.3%. The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Aptose Biosciences will report full-year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.64) to ($0.51). For the next year, analysts expect that the company will report earnings of ($0.60) per share, with EPS estimates ranging from ($0.64) to ($0.53). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. During the same quarter in the previous year, the firm posted ($0.18) EPS.

Several equities analysts have recently weighed in on APTO shares. StockNews.com raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Aptose Biosciences in a report on Friday, April 1st. Finally, HC Wainwright restated a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, March 23rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $7.50.

Several institutional investors have recently modified their holdings of APTO. WealthShield Partners LLC grew its stake in Aptose Biosciences by 40.8% in the 4th quarter. WealthShield Partners LLC now owns 104,920 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 30,408 shares during the last quarter. Two Sigma Investments LP purchased a new position in Aptose Biosciences in the third quarter valued at approximately $477,000. 683 Capital Management LLC raised its holdings in Aptose Biosciences by 42.1% in the third quarter. 683 Capital Management LLC now owns 3,112,737 shares of the biotechnology company’s stock valued at $6,786,000 after buying an additional 921,530 shares during the period. Goldman Sachs Group Inc. raised its holdings in Aptose Biosciences by 12.5% in the third quarter. Goldman Sachs Group Inc. now owns 751,802 shares of the biotechnology company’s stock valued at $1,639,000 after buying an additional 83,314 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Aptose Biosciences in the third quarter valued at approximately $1,576,000. Institutional investors and hedge funds own 34.21% of the company’s stock.

Shares of NASDAQ APTO traded down $0.01 during trading on Monday, hitting $1.06. The company had a trading volume of 3,235 shares, compared to its average volume of 421,274. The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.44. Aptose Biosciences has a fifty-two week low of $0.90 and a fifty-two week high of $5.78. The firm has a market capitalization of $97.76 million, a price-to-earnings ratio of -1.60 and a beta of 1.50.

About Aptose Biosciences (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.